SCM
KRYS icon

Shelton Capital Management’s Krystal Biotech KRYS Stock Holding History

Shelton Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$267K Sell
718
-122
-15% -$36.5K ﹤0.01% 589
2026
Q1 		$217K Hold
840
– – ﹤0.01% 635
2025
Q4 		$207K Buy
+840
New +$177K ﹤0.01% 657

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Shelton Capital Management's KRYS Position: Q2 2026 in Review

Shelton Capital Management reduced its Krystal Biotech (KRYS) stake by 15% in Q2 2026, selling an estimated $36.5K and leaving 718 shares worth $267K. The position accounts for ﹤0.01% of the portfolio, ranked #589.

Shelton Capital Management first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Shelton Capital Management held 718 shares of Krystal Biotech worth $267K as of Q2 2026.
  • Shelton Capital Management sold 122 Krystal Biotech shares in Q2 2026, an estimated $36.5K.
  • Krystal Biotech made up ﹤0.01% of Shelton Capital Management's portfolio in Q2 2026, its #589 holding.
  • Shelton Capital Management first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Shelton Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.